View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
February 3, 2020updated 12 Jul 2022 11:58am

Non-industry-sponsored clinical trials landscape: 2019

By GlobalData Healthcare

A clinical trial can be sponsored by an industry (company) or non-industry (government, individual/investigator-initiated, or institution).

Free Whitepaper
img

Disruptive start-ups to watch out for

2021 was a record-breaking year, with more businesses breaking into the billion-dollar club. Many start-ups have achieved or retained the unicorn status by the end of the year to reflect nearly a fivefold growth from that in 2020. This boom can be linked to a financing frenzy spurred by the quick adoption of technology and innovative solutions by start-ups gaining traction in response to the pandemic. However, the start-up ecosystem is now facing turbulent times for fundraising as investors seek long-term business strategies, valuations, and a route to profitability amid uncertain market circumstances. Nevertheless, 2022 has the potential to carry forward the momentum with multiple entities having a fair chance of being in the right place when aided by the right technologies. GlobalData leverages the power of alternative data to examine the health of start-ups across multiple dimensions including the quality of their innovations, market presence, and the funding they can attract. This helps our clients to analyze the disruptive potential of start-ups for early alliances, investments, and acquisition prospects to develop future-proof strategic roadmaps for a competitive advantage. Read our report and gather insights on the following topics:
  • Recent Unicorn trends
  • Unicorns in 2022
  • Future Unicorns
  • Start-ups to watch out for
Start-up ecosystem outlook by top geographies
by GlobalData
Enter your details here to receive your free Whitepaper.

Figure one: Non-industry-sponsored clinical trials by year. Credit: GlobalData.

When looking at non-industry-sponsored clinical trials since 2017, there has been a steady increase, from 32.1% of all clinical trials that year to 34.5% in 2019. This can be seen in figure one.

An analysis can be completed for those non-industry-sponsored clinical trials in 2019 by using the clinical trials database of GlobalData’s Pharma Intelligence Centre. In this article, a small number of phase zero, phase one / two, phase two / three and phase three / four trials were combined with phase one, phase two, phase three and phase four trials, respectively.

Figure two: 2019 non-industry-sponsored clinical trials by phase. Credit: GlobalData.

When looking at non-industry-sponsored clinical trials in 2019 in the database, it can be seen that phase two clinical trials outnumbered all other phases. Phase two clinical trials made up 49.7% of all clinical trials in 2019, with phase four following with 19.4%, phase one next with 16.4% and phase three with 14.5%. This can be seen in figure two.

Figure three: 2019 non-industry-sponsored clinical trials by therapy area. Credit: GlobalData.

Lastly, oncology was the top therapy area for non-industry sponsored clinical trials in 2019, as can be seen in figure three. They made up 25.7% of all clinical trials. The central nervous system (CNS) was second with 23.5%, followed by cardiovascular (8.9%), infectious disease (8.5%) and metabolic disorders (7.4%). Oncology, CNS, cardiovascular and infectious disease clinical trials all showed an increase in 2019 from 2018.

Related Companies

Free Whitepaper
img

Disruptive start-ups to watch out for

2021 was a record-breaking year, with more businesses breaking into the billion-dollar club. Many start-ups have achieved or retained the unicorn status by the end of the year to reflect nearly a fivefold growth from that in 2020. This boom can be linked to a financing frenzy spurred by the quick adoption of technology and innovative solutions by start-ups gaining traction in response to the pandemic. However, the start-up ecosystem is now facing turbulent times for fundraising as investors seek long-term business strategies, valuations, and a route to profitability amid uncertain market circumstances. Nevertheless, 2022 has the potential to carry forward the momentum with multiple entities having a fair chance of being in the right place when aided by the right technologies. GlobalData leverages the power of alternative data to examine the health of start-ups across multiple dimensions including the quality of their innovations, market presence, and the funding they can attract. This helps our clients to analyze the disruptive potential of start-ups for early alliances, investments, and acquisition prospects to develop future-proof strategic roadmaps for a competitive advantage. Read our report and gather insights on the following topics:
  • Recent Unicorn trends
  • Unicorns in 2022
  • Future Unicorns
  • Start-ups to watch out for
Start-up ecosystem outlook by top geographies
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena